New combo therapy shows promise for rare lung cancer

NCT ID NCT06155279

Ongoing Disease control Sponsor: Istituto Oncologico Veneto IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a combination of the immunotherapy drug pembrolizumab and chemotherapy before surgery can help people with a rare cancer called pleural mesothelioma. The trial involves 41 adults with early-stage disease that can be surgically removed. The main goal is to see if this approach can eliminate all cancer cells in the removed tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPHASIC PLEURAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mesothelioma, Malignant pleural biphasic mesothelioma pleural epithelioid mesothelioma pleural mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLEURAL MESOTHELIOMA

Contacts and locations

Locations

Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo

Alessandria, Italy
Azienda Ospedaliera-Universitaria di Parma

Parma, Italy
Azienda Ospedaliero-Universitaria S. Anna

Ferrara, Italy
Centro di Riferimento Oncologico (CRO) IRCCS

Aviano, Pordenone, Italy
Humanitas Gavazzeni

Bergamo, Italia/Bergamo, 24125, Italy
IFO - Istituto Tumori Regina Elena, Roma

Roma, Italia/Roma, 00144, Italy
Istituto Clinico Humanitas

Rozzano, Milano, 20089, Italy
Istituto Oncologico Veneto IRCCS

Padova, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.